



FOR IMMEDIATE RELEASE

TSX: BMR

**BRADMER EXECUTIVE TO PRESENT AT THE TECHNOLOGY
TRANSFER FOR BIOPHARMACEUTICALS CONFERENCE**

Toronto, Ontario – February 14, 2007 – Bradmer Pharmaceuticals Inc., a biopharmaceutical company dedicated to the development and commercialization of cancer therapies, announced today that Dr. Kerry Barnhart, President and Chief Scientific Officer of the Company will address the Technology Transfer for Biopharmaceuticals Conference organized by IBC Life Sciences on February 27th, 2007 in Carlsbad, California.

Dr. Barnhart, will be discussing strategies for the successful commercialization of antibody technologies derived from university research. Dr. Barnhart has been an instrumental leader in the preparation and design of Bradmer's Phase III multi-center trial set to begin mid-year of Neuradiab, Iodine (131-I) antitenascin monoclonal antibody 81C6. Bradmer acquired Neuradiab from Duke University, where over US\$60 million in research grants and related support has produced a series of Phase I and Phase II clinical trials on Neuradiab and closely related technologies. Approximately 200 brain cancer patients, including over 160 with glioblastoma multiforme, have been treated with the Neuradiab therapy regimen, and survival benefits have significantly exceeded historical controls in each completed trial.

About Bradmer Pharmaceuticals Inc. (www.bradmerpharma.com)

Bradmer Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of new and innovative cancer therapies. Bradmer's lead clinical candidate, Neuradiab, was developed at Duke University Medical Center as a proprietary therapy for a particularly aggressive form of brain cancer, glioblastoma multiforme. To date, over US\$60 million in grants and related support has driven research and development of the licensed treatment, which has been delivered to over 200 patients with promising results and has completed Phase II clinical trials at Duke University. Bradmer is currently in the process of organizing a Phase III multi-center clinical trial of the licensed treatment. Neuradiab has been granted Orphan Drug Status by both the U.S. Food and Drug Administration and the European Medicines Agency.

Bradmer Pharmaceuticals Inc.'s common shares have not been registered under the Securities Act of 1933, as amended (the "Securities Act") or any state regulatory agency in the United States. The resale or transfer by a U.S. investor of such common shares of Bradmer Pharmaceuticals Inc. is subject to the requirements of Rule 904 of Regulation S of the Securities Act or such other applicable exemption thereunder, and other applicable state securities laws.

Except for historical information, this press release may contain forward-looking statements, which reflect the Company's current expectation regarding future events. These forward-looking statements involve risk and uncertainties, which may cause but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process and other risks detailed from time to time in the Company's ongoing quarterly and annual reporting.

For further information contact:

Bradmer Pharmaceuticals Inc.
Mr. Brian Brohman
Chief Financial Officer
Phone: (502) 657-6038
Fax: (502) 657-6039

Investor Relations
Ross Marshall
The Equicom Group Inc.
Phone: (416) 815-0700 (Ext. 238)
Fax: (416) 815-0080

E-mail: bbrohman@bradmerpharma.com
Internet: www.bradmerpharma.com

E-mail: rmarshall@equicomgroup.com